Bioline Rx Ltd BLRX

NAS: BLRX | ISIN: US09071M2052   30/04/2025
3,470 USD (+7,76%)
(+7,76%)   30/04/2025

31 maart 2025 · BioLineRx Reports 2024 Financial Results and Provides Corporate Update · Persbericht

24 maart 2025 · BioLineRx to Report 2024 Annual Results on March 31, 2025 · Persbericht

15 augustus 2024 · BioLineRx Reports Second Quarter 2024 Financial Results and Recent Corporate and Portfolio Updates · Persbericht

8 augustus 2024 · BioLineRx to Report Second Quarter 2024 Results on August 15, 2024 · Persbericht

30 mei 2024 · BioLineRx Announces Clinical Trial Agreement with St. Jude Children's Research Hospital, Inc. to Evaluate Motixafortide for CD34+ Hematopoietic Stem Cell (HSC) Mobilization For Gene Therapy Applications in Sickle Cell Disease (SCD) · Persbericht

28 mei 2024 · BioLineRx Reports First Quarter 2024 Financial Results and Recent Corporate and Portfolio Updates · Persbericht

24 mei 2024 · BioLineRx Announces Abstract on Pilot Study Data from Phase 2 Combination Clinical Trial Evaluating Motixafortide in First-Line Pancreatic Cancer (PDAC) at American Society of Clinical Oncology (ASCO) 2024 Annual Meeting · Persbericht

22 mei 2024 · BioLineRx to Report First Quarter 2024 Results on May 28, 2024 · Persbericht

17 mei 2024 · BioLineRx Announces Receipt of Nasdaq Minimum Bid Price Notification · Persbericht

6 mei 2024 · BioLineRx Announces Poster Presentation on Economic Model Data for APHEXDA® (motixafortide) as part of CD34+ Hematopoietic Stem Cell Mobilization in Patients with Multiple Myeloma at ISPOR 2024 · Persbericht

17 april 2024 · BioLineRx Announces Poster Presentation on Apheresis Center Efficiency and CXCR4 Antagonists including APHEXDA® (motixafortide) in Patients with Multiple Myeloma at the ASFA 2024 Annual Meeting · Persbericht

10 april 2024 · BioLineRx Accesses Second Tranche of $20 Million Under Previously Announced $40 Million Non-Dilutive Debt Financing Agreement · Persbericht

1 april 2024 · BioLineRx Announces $6 Million Registered Direct Offering · Persbericht

26 maart 2024 · BioLineRx Reports 2023 Financial Results and Recent Corporate and Portfolio Updates · Persbericht

20 maart 2024 · BioLineRx to Report 2023 Annual Financial Results on March 26, 2024 · Persbericht

4 maart 2024 · BioLineRx Strengthens Intellectual Property Estate with Notice of Allowance for U.S. Patent Covering Method of Manufacturing Motixafortide (BL-8040) Suitable for Large Scale Production · Persbericht

28 februari 2024 · BioLineRx Announces First Patient Dosed in Randomized Phase 2 Combination Clinical Trial Evaluating Motixafortide in First-Line Pancreatic Cancer (PDAC) · Persbericht

16 februari 2024 · BioLineRx Announces Acceptance of Two Poster Presentations on APHEXDA® (motixafortide) for CD34+ Hematopoietic Stem Cell (HSC) Mobilization in Patients with Multiple Myeloma at the 2024 Tandem Meetings of ASTCT® and CIBMTR® · Persbericht

21 december 2023 · BioLineRx Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating Motixafortide for CD34+ Hematopoietic Stem Cell Mobilization for Gene Therapies in Sickle Cell Disease · Persbericht

13 november 2023 · BioLineRx to Report Third Quarter 2023 Results on November 20, 2023 · Persbericht

Mijn selecties